Quoin says EMA grants orphan drug designation for QRX003 in peeling skin syndrome
Quoin Pharmaceuticals received EMA orphan drug designation for QRX003 to treat Peeling Skin Syndrome. Status supports protocol guidance, fee reductions, EU grant access; provides 10-year EU market exclusivity upon approval. First formal clinical trial in Peeling Skin Syndrome remains on track to start before year-end. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief via (Ref. ID: 202610140630PRIMZONEFULLFEED9845261) on October 14, 2026, and is solely responsible for the information contained therein. (C)
Quoin Pharmaceuticals received EMA orphan drug designation for QRX003 to treat Peeling Skin Syndrome. Status supports protocol guidance, fee reductions, EU grant access; provides 10-year EU market exclusivity upon approval. First formal clinical trial in Peeling Skin Syndrome remains on track to start before year-end. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence.
While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief via (Ref. ID: 202610140630PRIMZONEFULLFEED9845261) on October 14, 2026, and is solely responsible for the information contained therein.
(C)